Almirall (OTCMKTS:LBTSF – Get Free Report) is expected to issue its resultson Friday, July 24th. Analysts expect the company to post earnings of $0.1485 per share and revenue of $357.4080 million for the quarter.
Almirall Stock Performance
Almirall stock opened at $15.35 on Wednesday. The stock’s 50-day moving average is $15.35 and its 200-day moving average is $15.37. Almirall has a 12 month low of $13.36 and a 12 month high of $15.47.
Almirall Company Profile
Almirall is a research-driven pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943, the firm has evolved into a specialist in dermatology, dedicating its efforts to understanding and treating a range of inflammatory and chronic skin conditions. Over the decades, Almirall has built a reputation for its targeted R&D approach and its commitment to improving patient outcomes in dermatological care.
The company’s core activities span the research, development, manufacturing and marketing of prescription therapies for skin diseases.
Recommended Stories
- Five stocks we like better than Almirall
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Almirall Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Almirall and related companies with MarketBeat.com's FREE daily email newsletter.
